Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eritromax vs Eprex in Anemia Secondary to CKD
NCT01695759Phase 3Terminated
- Sponsor
- Azidus Laboratories Limited
- Start
- Dec 2013
- Primary completion
- Dec 2014
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Eritromax in anemia of chronic kidney disease (CKD-A) (2 arms), sponsored by Azidus Laboratories Limited. Primary endpoint: Change of hemoglobin levels at correction phase at 6 months. Started Dec 2013; status: terminated.
02
Drugs
Eritromax
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT01695759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01695759.